BIOMARIN PHARMACEUTICAL INC Debt Securities, Available-for-sale, Amortized Cost
BIOMARIN PHARMACEUTICAL INC (BMRN) had Debt Securities, Available-for-sale, Amortized Cost of $874.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $874.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $3.07B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $2.05B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $1.99B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $874.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.07B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $2.05B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.99B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.94B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.78B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $1.66B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.48B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.78B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $1.67B 10-Q · filed 2024-04-26 |
| 2023-12-31 | $1.68B 10-K · filed 2025-02-24 |
| 2023-09-30 | $1.68B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.57B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $1.50B 10-Q · filed 2023-04-28 |
| 2022-12-31 | $1.64B 10-K · filed 2024-02-26 |
| 2022-09-30 | $1.67B 10-Q · filed 2022-10-28 |
| 2022-06-30 | $1.54B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.53B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $1.52B 10-K · filed 2023-02-27 |
| 2021-09-30 | $1.54B 10-Q · filed 2021-10-29 |
| 2021-06-30 | $1.47B 10-Q · filed 2021-07-30 |
| 2021-03-31 | $1.41B 10-Q · filed 2021-04-30 |
| 2020-12-31 | $1.35B 10-K · filed 2022-02-25 |
| 2020-09-30 | $1.76B 10-Q · filed 2020-11-06 |
| 2020-06-30 | $1.69B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.15B 10-Q · filed 2020-05-01 |
| 2019-12-31 | $1.16B 10-K · filed 2021-02-26 |
| 2019-09-30 | $1.15B 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $1.10B 10-Q · filed 2019-08-02 |
| 2019-03-31 | $1.21B 10-Q · filed 2019-04-29 |
| 2018-12-31 | $1.32B 10-K · filed 2020-02-27 |
| 2018-09-30 | $1.65B 10-Q · filed 2018-10-26 |
| 2017-12-31 | $1.79B 10-K · filed 2019-02-28 |
| 2015-03-31 | $332.04M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $167.56M 10-Q · filed 2015-05-05 |
| 2014-09-30 | $716.70M 10-Q · filed 2014-10-28 |
| 2013-12-31 | $483.64M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |